Pharmaceutical companies including Baxter, Biogen Idec and GlaxoSmithKline, through its SR One subsidiary, all backed the round, which also included funds from True Norths' parent company iPierian.
True North Therapeutics, a US-based biotechnology company developing therapies to treat rare diseases, closed a $22m series A round today backed by several healthcare corporates.
In addition to incorporating funds from the spin-out of True North from drug developer iPierian in 2013, the round also included corporate venturing units SR One, Biogen Idec New Ventures and Baxter Ventures, and venture capital firms Kleiner Perkins Caufield & Byers and MPM Capital.
True North will invest the funding in advance its lead…
